Comparative Pharmacology
Head-to-head clinical analysis: ATACAND versus EDARBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND versus EDARBI.
ATACAND vs EDARBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.
EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.
None Documented
None Documented
Terminal half-life is approximately 9 hours (range 5-11 hours). In elderly patients, half-life may be prolonged. No accumulation upon repeated dosing.
Approximately 20-22 hours in normal subjects; allows once-daily dosing. Half-life increases in moderate to severe hepatic impairment.
Renal (60% unchanged), biliary/fecal (40% as camdhesartan). Approximately 33% of the dose is excreted in urine as unchanged drug, and the remainder as inactive metabolites via bile and feces.
Approximately 60% of dose is excreted in feces (primarily as unchanged drug) and 33% in urine (as metabolites, predominantly glucuronide conjugates).
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker